Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Aliment Pharmacol Ther ; 41(3): 310-9, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25982037

ABSTRACT

BACKGROUND: Results are conflicting with respect to the renal effects of anti-viral agents used for hepatitis B virus infection. AIM: To compare short and long-term renal effects in real-life settings and to determine risk factors for renal impairment during treatment. METHODS: 2221 treatment-naïve patients were enrolled. Among these, 895 (302 lamivudine, 27 telbivudine, 282 entecavir, 273 tenofovir and 11 adefovir initiated patients) had 'repeated measures' of creatinine (baseline, 1st, 6th, 12th and 24th month of treatment). Telbivudine and adefovir groups were excluded from further analysis because of the low number of patients. We calculated the glomerular filtration rate (GFR) using the Modification of Diet in Renal Disease (MDRD) formula at each time point. Hypophosphataemia was also recorded. Risk factors for renal impairment were analysed. RESULTS: Tenofovir caused a decline in GFR at each time point when compared to baseline levels. However, lamivudine and entecavir did not change GFR. GFR-shifting from ≥90 to 60-89 mL/min/1.73 m(2) was comparable among groups. The proportion of patients whose baseline creatinine increased more than 25% was comparable among all anti-virals. GFR showed a decline in patients who switched from entecavir to tenofovir. One patient with compensated cirrhosis needed to change from tenofovir because of renal safety. Seven and three patients developed transient hypophosphataemia in the tenofovir and lamivudine groups, respectively. CONCLUSIONS: Although tenofovir caused a decline in GFR, differences between the anti-viral agents do not appear to be so impressive. In patients with and without renal risk factors at baseline, there is no impact of anti-virals, including tenofovir.


Subject(s)
Antiviral Agents/therapeutic use , Hepatitis B, Chronic/drug therapy , Liver Cirrhosis/etiology , Renal Insufficiency/chemically induced , Adult , Antiviral Agents/adverse effects , Creatinine/metabolism , Female , Glomerular Filtration Rate , Hepatitis B virus/isolation & purification , Humans , Liver Cirrhosis/drug therapy , Male , Middle Aged , Renal Insufficiency/epidemiology , Risk
2.
Acta Clin Belg ; 70(1): 44-5, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25649531

ABSTRACT

Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive multisystem disorder caused by thymidine phosphorylase deficiency. Severe denutrition is almost constant during the course of the disease which leads to severe malnutrition and requires long-term parenteral nutrition in most cases. Patients with MNGIE syndrome and chronic intestinal pseudo-obstruction have a particularly poor prognosis and they usually die around 40 years of age. Gastrointestinal perforation associated with MNGIE is extremely rare. Herein we present our unique case with MNGIE associated abdominal esophageal perforation.


Subject(s)
Esophageal Perforation/etiology , Intestinal Pseudo-Obstruction/complications , Mitochondrial Encephalomyopathies/complications , Abdomen , Adult , Humans , Male , Muscular Dystrophy, Oculopharyngeal , Ophthalmoplegia/congenital
3.
West Indian Med J ; 65(2): 404-405, 2015 Dec 11.
Article in English | MEDLINE | ID: mdl-26907982

ABSTRACT

Ischaemic colitis results from a chronic or acute drop in the blood supply to the bowel and accounts for 6‒18% of the causes of acute lower gastrointestinal bleeding. Diabetes mellitus, hypotension, advanced age, aortic surgery and peripheral vascular disease have also been suggested to be predisposing factors for ischaemic colitis (1). In this report, we present a case of ischaemic colitis in haemodialysis with a good response to conservative treatment.

SELECTION OF CITATIONS
SEARCH DETAIL
...